Literature DB >> 25219104

Tolerated sting challenge in patients on Hymenoptera venom immunotherapy improves health-related quality of life.

D S Koschel, M Schmies, C Nink Weber, G Höffken, F Balck.   

Abstract

BACKGROUND: Sting challenge with a live insect remains the best test for proving the efficacy of immunotherapy in Hymenoptera allergy.
OBJECTIVE: We studied the impact of tolerated sting challenge on quality of life. PATIENTS AND METHODS: In this prospective study, data were collected via self-report questionnaires completed by consenting patients with Hymenoptera venom allergy on venom immunotherapy before and after a sting challenge.
RESULTS: The study population comprised 100 adult patients (82 with yellow jacket allergy and 18 with honeybee allergy) who participated between September 2009 and November 2010. After the sting challenge, the score on the Vespid Allergy Quality of Life Questionnaire revealed a statistically significant improvement (mean [SD] change, 0.73 [0.98]; P < .0001; 95% CI, 0.52-0.94). This improvement was independent of the patients' gender and age and the severity of the initial anaphylactic reaction. A statistically significant improvement was documented in 2 subgroups of the Short Form 36 Health Survey (physical functioning, mean change, -5.78 [25.23]; P = .038; 95% CI, -11.22 to -0.34; vitality, mean change -4.29 [12.49]; P =.002; 95% CI, -7.02 to -1.57).
CONCLUSIONS: Sting challenge results in a significant improvement in disease-specific quality of life and subgroups of general quality of life in patients allergic to Hymenoptera venom receiving established venom immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25219104

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  5 in total

1.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 2.  Patient's Adherence and Compliance and Quality of Life During/After VIT.

Authors:  Cristoforo Incorvaia; Enrico Heffler; Silvia Peveri; Francesco Pucciarini; Giorgio Walter Canonica; Erminia Ridolo
Journal:  Front Allergy       Date:  2022-06-28

3.  Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.

Authors:  Tamara Eitel; Kim Nikola Zeiner; Katharina Assmus; Hanns Ackermann; Nadja Zoeller; Markus Meissner; Roland Kaufmann; Stefan Kippenberger; Eva Maria Valesky
Journal:  World Allergy Organ J       Date:  2021-04-21       Impact factor: 4.084

Review 4.  Stinging insect allergy: current perspectives on venom immunotherapy.

Authors:  Sian W Ludman; Robert J Boyle
Journal:  J Asthma Allergy       Date:  2015-07-23

5.  2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.

Authors:  F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh
Journal:  World Allergy Organ J       Date:  2015-10-28       Impact factor: 4.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.